Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
Biotech Connection Singapore (BCS) is a non-profit, professional-led organization that connects the local biotech and life sciences community.
We sat down with Saziye Yorulmaz Avsar, Vice President Insights at Biotech Connection Singapore (BCS) to understand what her key challenges are in her field of work and how PatSnap’s AI-powered patent database can help her team solve some of the most critical challenges in the biotech space.
In today’s biotech ecosystem, innovation doesn’t happen in isolation. It sits at the intersection of science, IP, clinical progress, and commercial strategy.
For BCS, this complexity was part of everyday work.
As a key player connecting academia, industry, and government, BCS supports organizations in answering high-stakes questions:
But answering these questions wasn’t easy as every strategic recommendation bore a hidden burden: fragmented data scattered across dozens of disconnected platforms.
To build a single view of an opportunity, the BCS team had to comb through numerous public databases and tools, with each covering only one part of the entire landscape. It was time consuming and labor intensive. The team ran parallel searches across different platforms, manually extracting data and pieces of information together in spreadsheets.
The lack of connectivity between datasets made things even more challenging as the team needed to put in extra effort to link a biological target to its patent landscape, map IP positions against clinical development progress and make connections to how innovation translated into commercial opportunity.
What should have been strategic work became operational overhead.
BCS realized that the issue wasn’t just data access but data integration.
They didn’t need more tools.
They needed one platform that could connect science, IP, clinical data, deals and market intelligence.
All in a way that enables strategic decision-making, not just data collection.
With PatSnap, BCS transformed how they approached research and strategy.
Instead of navigating fragmented systems, they gained access to a centralized intelligence platform that integrates technical, legal and commercial intelligence where they can quickly identify potential assets using advanced filtering tools, benchmark deals using structured transaction data and payment trends, track the full lifecycle of innovation, from academic research and funding through to clinical development. This allowed BCS to conduct due diligence much more efficiently, as key datasets are already connected.
The team also used tools like Organization Heatmaps and Pipeline Landscapes to translate complex datasets into clear visuals for consulting reports and investor presentations.
Diagram 1
Source: PatSnap Synapse
Diagram 1 shows the radial pipeline landscape highlights the ten most active organizations in RNAi therapeutics development, ranked by the number of drug candidates across all clinical stages from Preclinical to Approved. Alnylam Pharmaceuticals, Inc. leads the competitive landscape with multiple approved assets, including Patisiran sodium, Givosiran Sodium, and Vutrisiran Sodium, alongside a broad early-stage pipeline. Arrowhead Pharmaceuticals, Novartis AG, and Novo Holdings similarly demonstrate significant pipeline depth, spanning both early and late stages of clinical development.
Diagram 2
Source: PatSnap Synapse
Diagram 2 shows the small molecule drugs dominate global clinical development with nearly 10,000 trials, followed by protein drugs and antibodies at approximately 4,000 each. Monoclonal antibodies rank fourth, while emerging modalities such as bispecific antibodies, ADCs, and cell and gene therapies occupy the lower rankings. Across all drug types, activity is concentrated in Early Phase 1 through Phase 2, indicating a pipeline still largely in early-to-mid stage development.
Diagram 3
Source: PatSnap Discovery
Diagram 3 consists of a bubble chart tracks annual patent filings by key new entrants in the RNAi therapeutics space, with bubble size reflecting filing volume. Switch Therapeutics recorded the highest single-year activity with 31 filings in 2022, which stands out as the peak filing year across most organizations. Activity has broadly moderated from 2023 onward, with Sanegene Bio USA and Microbio (Shanghai) among the few maintaining consistent output through 2024–2025
PatSnap’s suite of analytical tools such as PatSnap Synapse has helped BCS to spot market gaps instantly, identify emerging competitors in the space and uncover partnership opportunities.
What once required hours and days of analysis became immediately visible in seconds.
The platform removes the need to manually stitch datasets together from multiple sources and automatically generates competitive landscapes and visual analyses.
The team could also make decisions more confidently as their recommendations are supported by verified and comprehensive information, rather than fragmented sources where the risk of missing hidden competitor intelligence or overlapping IP positions run high.
Additionally, they could also identify early academic innovations before they appear in clinical pipelines by linking translation research with patent data.
Today, BCS uses PatSnap to power:
For BCS, this transformation is just the beginning. With PatSnap’s AI powered patent intelligence database platform, they can now move from reactive analysis to predictive insight.
These tools will help the biotechnology industry de-risk innovation and accelerate the translation of research into real therapeutic solutions.
In a world where innovation is increasingly complex, the advantage doesn’t come from having more data.
It comes from connecting the dots faster than anyone else.
And for BCS, that shift has already begun.
Saziye Yorulmaz Avsar, VP Insights, BCS
Patsnap helped BCS transform their approach to research and strategy. Instead of navigating fragmented systems, they gained access to a centrcentralized intelligence platform that integrates technical, legal and commercial intelligence where they can quickly identify potential assets using advanced filtering tools, benchmark deals using structured transaction data and payment trends, track the full lifecycle of innovation, from academic research and funding through to clinical development.
